AU2018274589A1 - Neurotrophins for use in the treatment of hearing loss - Google Patents
Neurotrophins for use in the treatment of hearing loss Download PDFInfo
- Publication number
- AU2018274589A1 AU2018274589A1 AU2018274589A AU2018274589A AU2018274589A1 AU 2018274589 A1 AU2018274589 A1 AU 2018274589A1 AU 2018274589 A AU2018274589 A AU 2018274589A AU 2018274589 A AU2018274589 A AU 2018274589A AU 2018274589 A1 AU2018274589 A1 AU 2018274589A1
- Authority
- AU
- Australia
- Prior art keywords
- neurotrophin
- ngf
- use according
- composition
- previous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title claims abstract description 105
- 102000007072 Nerve Growth Factors Human genes 0.000 title claims abstract description 53
- 208000016354 hearing loss disease Diseases 0.000 title claims abstract description 21
- 238000011282 treatment Methods 0.000 title claims abstract description 21
- 206010011878 Deafness Diseases 0.000 title claims abstract description 20
- 231100000888 hearing loss Toxicity 0.000 title claims abstract description 17
- 230000010370 hearing loss Effects 0.000 title claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 230000006378 damage Effects 0.000 claims abstract description 10
- 206010033109 Ototoxicity Diseases 0.000 claims abstract description 8
- 231100000262 ototoxicity Toxicity 0.000 claims abstract description 8
- 208000016621 Hearing disease Diseases 0.000 claims abstract description 7
- 206010061373 Sudden Hearing Loss Diseases 0.000 claims abstract description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 51
- 239000011859 microparticle Substances 0.000 claims description 21
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 16
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 16
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 9
- 108090000742 Neurotrophin 3 Proteins 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 102000003683 Neurotrophin-4 Human genes 0.000 claims description 7
- 108090000099 Neurotrophin-4 Proteins 0.000 claims description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 7
- 229940032018 neurotrophin 3 Drugs 0.000 claims description 7
- 229940097998 neurotrophin 4 Drugs 0.000 claims description 7
- 241001529936 Murinae Species 0.000 claims description 6
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 4
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960004584 methylprednisolone Drugs 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 102100029268 Neurotrophin-3 Human genes 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229940053128 nerve growth factor Drugs 0.000 description 41
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 210000003027 ear inner Anatomy 0.000 description 14
- 239000003814 drug Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 210000002569 neuron Anatomy 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 210000000959 ear middle Anatomy 0.000 description 8
- 210000003477 cochlea Anatomy 0.000 description 7
- 210000002768 hair cell Anatomy 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004230 Neurotrophin 3 Human genes 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 5
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 5
- 229930182566 Gentamicin Natural products 0.000 description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 229960002518 gentamicin Drugs 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 210000003454 tympanic membrane Anatomy 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000012537 formulation buffer Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004049 perilymph Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 102000046917 human NGF Human genes 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000001323 spiral ganglion Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 206010011903 Deafness traumatic Diseases 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 208000030768 Optic nerve injury Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003984 auditory pathway Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000006721 cell death pathway Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 210000000860 cochlear nerve Anatomy 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002266 hair cells auditory Anatomy 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 206010069732 neurotrophic keratopathy Diseases 0.000 description 1
- 210000002985 organ of corti Anatomy 0.000 description 1
- 231100000199 ototoxic Toxicity 0.000 description 1
- 230000002970 ototoxic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 230000005236 sound signal Effects 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 102000015534 trkB Receptor Human genes 0.000 description 1
- 108010064880 trkB Receptor Proteins 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17172659.9A EP3406259A1 (en) | 2017-05-24 | 2017-05-24 | Neurotrophins for use in the treatment of hearing loss |
| EP17172659.9 | 2017-05-24 | ||
| PCT/EP2018/063310 WO2018215414A1 (en) | 2017-05-24 | 2018-05-22 | Neurotrophins for use in the treatment of hearing loss |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018274589A1 true AU2018274589A1 (en) | 2019-11-28 |
Family
ID=58772736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018274589A Abandoned AU2018274589A1 (en) | 2017-05-24 | 2018-05-22 | Neurotrophins for use in the treatment of hearing loss |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200155647A1 (https=) |
| EP (2) | EP3406259A1 (https=) |
| JP (1) | JP2020520956A (https=) |
| KR (1) | KR20200011951A (https=) |
| CN (1) | CN110691607A (https=) |
| AU (1) | AU2018274589A1 (https=) |
| BR (1) | BR112019024504A2 (https=) |
| CA (1) | CA3062744A1 (https=) |
| IL (1) | IL270701A (https=) |
| RU (1) | RU2019137430A (https=) |
| WO (1) | WO2018215414A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4093387A4 (en) * | 2020-01-24 | 2024-04-24 | Dompé farmaceutici S.p.A. | GROWTH FACTOR FORMULATION FOR A CONDITION ASSOCIATED WITH AN OTIC EVENT |
| WO2022221351A1 (en) * | 2021-04-13 | 2022-10-20 | Dompé Farmaceutici S.P.A. | Treatment of neuropathic corneal pain with ngf |
| PL4452267T3 (pl) * | 2021-12-23 | 2025-06-23 | Cilcare Dev | Pochodne 4-fenylo-tetrahydropirydyny do leczenia chorób słuchu |
| EP4316505A1 (en) * | 2022-08-05 | 2024-02-07 | Dompé farmaceutici S.p.a. | Intranasal administration of ngf for the treatment of sensorineural hearing loss |
| KR102851394B1 (ko) * | 2022-11-11 | 2025-09-04 | 단국대학교 천안캠퍼스 산학협력단 | 광반응성 하이드로젤을 이용한 분화유도인자 탑재 나노캡슐 |
| EP4501346A1 (en) * | 2023-08-04 | 2025-02-05 | Dompe' Farmaceutici S.P.A. | Method for the prevention of hearing loss induced by a platinum-based chemotherapy drug |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6225282B1 (en) * | 1996-01-05 | 2001-05-01 | Genentech, Inc. | Treatment of hearing impairments |
| US5929041A (en) * | 1996-02-23 | 1999-07-27 | Amgen Inc. | Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product |
| US6113947A (en) * | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
| ES2213861T3 (es) | 1998-10-09 | 2004-09-01 | Scil Proteins Gmbh | Procedimiento de obtencion de ngf-beta activa. |
| US7700111B2 (en) * | 2002-01-17 | 2010-04-20 | The Regents Of The University Of Michigan | Auditory nerve protection and re-growth |
| WO2009062149A1 (en) * | 2007-11-08 | 2009-05-14 | Creighton University | Methods for maintaining inner ear neurons |
| CN104203264B (zh) | 2011-12-19 | 2018-08-28 | 瓦克化学有限公司 | 新型proNGF突变体及其在生产β-NGF中的用途 |
| EP3328440A4 (en) * | 2015-07-28 | 2019-01-16 | Otonomy, Inc. | TREATMENT WITH REDUCED TRK-B AND TRK-C ANTAGONISTS |
| CA2993645A1 (en) * | 2015-07-28 | 2017-02-02 | Otonomy, Inc. | Trkb or trkc agonist compositions and methods for the treatment of otic conditions |
-
2017
- 2017-05-24 EP EP17172659.9A patent/EP3406259A1/en not_active Withdrawn
-
2018
- 2018-05-22 KR KR1020197035948A patent/KR20200011951A/ko not_active Ceased
- 2018-05-22 WO PCT/EP2018/063310 patent/WO2018215414A1/en not_active Ceased
- 2018-05-22 US US16/615,201 patent/US20200155647A1/en not_active Abandoned
- 2018-05-22 CA CA3062744A patent/CA3062744A1/en active Pending
- 2018-05-22 CN CN201880033628.8A patent/CN110691607A/zh active Pending
- 2018-05-22 JP JP2019564510A patent/JP2020520956A/ja active Pending
- 2018-05-22 BR BR112019024504-9A patent/BR112019024504A2/pt not_active IP Right Cessation
- 2018-05-22 EP EP18725242.4A patent/EP3630159A1/en not_active Withdrawn
- 2018-05-22 RU RU2019137430A patent/RU2019137430A/ru unknown
- 2018-05-22 AU AU2018274589A patent/AU2018274589A1/en not_active Abandoned
-
2019
- 2019-11-17 IL IL270701A patent/IL270701A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018215414A1 (en) | 2018-11-29 |
| KR20200011951A (ko) | 2020-02-04 |
| RU2019137430A (ru) | 2021-06-24 |
| EP3630159A1 (en) | 2020-04-08 |
| IL270701A (en) | 2020-01-30 |
| CN110691607A (zh) | 2020-01-14 |
| CA3062744A1 (en) | 2018-11-29 |
| EP3406259A1 (en) | 2018-11-28 |
| JP2020520956A (ja) | 2020-07-16 |
| RU2019137430A3 (https=) | 2021-08-30 |
| BR112019024504A2 (pt) | 2020-06-23 |
| US20200155647A1 (en) | 2020-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200155647A1 (en) | Neurotrophins for use in the treatment of hearing loss | |
| Herran et al. | In vivo administration of VEGF-and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson’s disease | |
| JP7033789B2 (ja) | トリグリセリド耳用製剤とその使用 | |
| KR101449785B1 (ko) | 귀 질환 및 병태를 치료하기 위한 귀 조제물 | |
| Noushi et al. | Delivery of neurotrophin-3 to the cochlea using alginate beads | |
| KR20180037994A (ko) | TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법 | |
| WO2010062413A1 (en) | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders | |
| García-Caballero et al. | Photoreceptor preservation induced by intravitreal controlled delivery of GDNF and GDNF/melatonin in rhodopsin knockout mice | |
| AU2009271129A1 (en) | Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders | |
| Yu et al. | Complete restoration of hearing loss and cochlear synaptopathy via minimally invasive, single-dose, and controllable middle ear delivery of brain-derived neurotrophic Factor–Poly (dl-lactic acid-co-glycolic acid)-loaded hydrogel | |
| CA3087574A1 (en) | Growth factor otic formulations | |
| US20080262415A1 (en) | Enhanced wound healing | |
| US20190374606A1 (en) | Neurotrophin mutants for treating hearing loss and other otic disorders | |
| JP2020520956A5 (https=) | ||
| AU2020230269B2 (en) | Auris formulations for treating otic diseases and conditions | |
| CN114845721A (zh) | 用于药物诱导的耳毒性的耳用制剂 | |
| EP4173630A1 (en) | Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease | |
| US20180221451A1 (en) | Long acting liraglutide compositions | |
| WO2011049954A2 (en) | Compositions comprising wnt modulators or neurotoxins for the treatment of otic disorders | |
| WO2021127275A1 (en) | Gsk-3 modulator otic formulations | |
| KR102653853B1 (ko) | 약물 전달용 나노서스펜션 및 이의 용도 | |
| TWI412370B (zh) | 用於治療耳疾病及症狀的耳配方 | |
| Hu | Survival and Axonal Regeneration of Retinal Ganglion Cells in a Mouse Optic Nerve Crush Model After a Delayed Cell-Based Intravitreal Co-Therapy with Ciliary Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor | |
| HK40006438A (en) | Triglyceride otic formulations and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |